PulseAugur
EN
LIVE 21:15:34
中文(ZH) 昂利康:获得依托考昔片药品注册证书

Angelikang Pharma Secures Approval for Etoricoxib Tablet in China

Angelikang Pharmaceutical has received approval from China's National Medical Products Administration for its etoricoxib tablet, a medication used to treat inflammatory conditions like osteoarthritis and gout. This approval marks a significant step for the company in the pharmaceutical market. The drug is indicated for symptomatic relief of acute and chronic inflammatory conditions, as well as acute gouty arthritis and primary dysmenorrhea. AI

RANK_REASON Product approval from a national regulatory body for a pharmaceutical. [lever_c_demoted from significant: ic=1 ai=0.0]

Read on 36氪 (36Kr) →

AI-generated summary · Google Gemini · from 1 sources. How we write summaries →

Angelikang Pharma Secures Approval for Etoricoxib Tablet in China

How we ranked this

Signal score
0 / 100
Composite score across the factors below. Higher = stronger signal that this story matters right now.
Newsworthiness bucket
Research
Product approval from a national regulatory body for a pharmaceutical. [lever_c_demoted from significant: ic=1 ai=0.0]
Source corroboration
Single-source cluster
Only one publisher covered this so far. Single-source stories can still rank when the publisher is high-authority, but they lack cross-source corroboration.
Topics
product, policy
Editorial topic classification. Feeds into how the story surfaces on /topic/<slug> hub pages and into the per-entity coverage mix.
AI-industry relevance
Low
Off-topic or adjacent — cluster remains reachable but doesn't surface in AI-industry rankings.
Story freshness
109 days old
Aged out of breaking-news scoring windows; ranking reflects the durable signal from the full source set.

Full methodology in our editorial standards.

COVERAGE [1]

  1. 36氪 (36Kr) TIER_1 中文(ZH) ·

    Anlikang: Obtains Etoricoxib Tablets Drug Registration Certificate

    36氪获悉,昂利康公告,公司近日收到国家药监局签发的依托考昔片《药品注册证书》。依托考昔片适用于治疗骨关节炎急性期和慢性期的症状和体征、急性痛风性关节炎和原发性痛经。